Ang Lifesciences India Ltd vs Astrazeneca Pharma India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of ANG Lifesciences India Ltd is ₹ 26.51 as of 18 May 09:19 . The P/E Ratio of ANG Lifesciences India Ltd changed from 6 on March 2022 to 0 on March 2025 . This represents a CAGR of -100.00% over 4 yearsThe P/E Ratio of Astrazeneca Pharma India Ltd changed from 0 on March 2022 to 0 on March 2025 . This represents a CAGR of 0.0% over 4 years The Market Cap of ANG Lifesciences India Ltd changed from ₹ 243.2 crore on March 2022 to ₹ 29.67 crore on March 2025 . This represents a CAGR of -40.90% over 4 yearsThe Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 0 crore on March 2022 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 4 years The revenue of ANG Lifesciences India Ltd for the Dec '25 is ₹ 18.89 crore as compare to the Sep '25 revenue of ₹ 26.18 crore. This represent the decline of -27.85% The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of ANG Lifesciences India Ltd for the Dec '25 is ₹ -2.53 crore as compare to the Sep '25 ebitda of ₹ 0.2 crore. This represent the decline of -1365% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of ANG Lifesciences India Ltd changed from ₹ -3.07 crore to ₹ -4.75 crore over 7 quarters. This represents a CAGR of 28.33% The net profit of Astrazeneca Pharma India Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of ANG Lifesciences India Ltd changed from 2.61 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 yearsThe Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 years .

About ANG Lifesciences India Ltd

ANG Lifesciences India Limited was originally incorporated as a Private Limited Company with the name 'ANG Lifesciences India Private Limited' on June 14, 2006.
On conversion into Public Limited Company, the name was changed to ANG Lifesciences India Limited on March 02, 2010.
The Company further converted into Private Limited Company and the name of the Company was changed to 'ANG Lifesciences India Private Limited' on September 22, 2010.
Subsequently, on conversion into Public Limited Company, the name again changed to 'ANG Lifesciences India Limited' on May 18, 2016. The Company is engaged in the business of manufacturing and marketing of finished pharmaceutical formulation in the form of Sterile Dry Powder Injection Vials.
In 2008-09, the Company started its commercial production.

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

FAQs for the comparison of ANG Lifesciences India Ltd and Astrazeneca Pharma India Ltd

Which company has a larger market capitalization, ANG Lifesciences India Ltd or Astrazeneca Pharma India Ltd?

Market cap of ANG Lifesciences India Ltd is 35 Cr while Market cap of Astrazeneca Pharma India Ltd is 21,221 Cr

What are the key factors driving the stock performance of ANG Lifesciences India Ltd and Astrazeneca Pharma India Ltd?

The stock performance of ANG Lifesciences India Ltd and Astrazeneca Pharma India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for ANG Lifesciences India Ltd and Astrazeneca Pharma India Ltd?

As of May 18, 2026, the ANG Lifesciences India Ltd stock price is INR ₹26.88. On the other hand, Astrazeneca Pharma India Ltd stock price is INR ₹8488.45.

How do dividend payouts of ANG Lifesciences India Ltd and Astrazeneca Pharma India Ltd compare?

To compare the dividend payouts of ANG Lifesciences India Ltd and Astrazeneca Pharma India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.